Drug Profile
Research programme: influenza virus vaccines - DSM
Alternative Names: Recombinant haemagglutinin influenza virus vaccine - DSMLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator DSM
- Class Antigens; Recombinant proteins; Vaccines; Viral proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype; Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A-virus-H1N1-subtype(Prevention) in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Influenza-virus-infections(Prevention) in USA
- 24 Apr 2013 Preclinical trials in Influenza-A virus H1N1 subtype (prevention) in USA (Parenteral)